Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Eli Lilly and Company Plans Houston, Texas, Manufacturing Operations

09/27/2025
Global pharmaceutical company Eli Lilly and Company plans to establish production operations in Houston, Texas. The $6.5 billion project is expected to create 615 jobs.

The investment will include the construction of a new active pharmaceutical ingredient (API) manufacturing facility, located at Generation Park, which will focus on the company's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience. Operations are scheduled to begin within five years.

"With this new chemical synthesis facility, we are expanding our vital advanced pharmaceutical capabilities in the U.S. and setting a new global benchmark for innovation and technical leadership in our industry," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "Additionally, we are committed to sustainability, being a responsible steward of natural resources, and strengthening the communities where our employees live and work."

A Texas Enterprise Fund (TEF) grant of $5.5 million has been extended to Lilly, and the project has been approved under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

"Texas is the best state in America for doing business," noted Governor Abbott. "This announcement by Lilly will boost pharmaceutical manufacturing in the state of Texas and ensure that we do not rely on other countries for the manufacturing and supply of medicines and medical supplies. Texas is doing its part to bring manufacturing capacity back to America and expanding biomedical manufacturing right here in our great state."

“This is a transformative moment for the Houston region and our life sciences industry,” added Greater Houston Partnership President and CEO Steve Kean. “The Lilly project represents one of the largest for-profit life sciences investments in Texas history and is a powerful endorsement of Houston’s growing position as a global hub for innovation, advanced manufacturing, and biomedical excellence. This win reflects years of strategic work by partners across the public and private sectors to build the talent, infrastructure, and business environment needed to attract world-class companies like Lilly.”

Exclusive Research